Table 1

	Total Cholesterol TC(mg/dl)	Triglyceride TG (mg/dl)	High density HDL (mg/dl)	Low density LDL (mg/dl)	LDL/HDL (mg/dl)	Coronary risk CT/HDL (mg/dl)
Control group (C)	56,84±9,66^bc	51,37±13,32^a	19,59±5,5^b	13,56±5,46^a	0,62±0,19^a	2,87±0,34^ab
Diabetic group (D)	61,77±4,71^c	63,77±3,75^b	15,66±6,92^a	17,05±7,61^a	1,06±0,83^a	3,94±0,60^c
D+C1	49, 6±17,49^ab	44,28±8,51^a	15,52±1,43^a	13,40± 6,24^a	0,87±0,64^a	3,19±0,12^bc
D+C2	46,90±7,51^a	40,29±14,89^a	16,24±2,67^a	12,24±8,23^a	0,74±0,48^a	2,82±0,32^a
D+C3	54,52±13,45^abc	51,47±19,88^ab	16,62±6,17^a	14,28±0,26^a	0,85±0,39^a	3,28±1,04^ab

Values are expressed as means ± SE (n=8). Values with different superscript letters (a, b, c) indicate signiﬁcant differences among groups at P<0.05 by Duncan’s multiple range test
C: Control; D: Rats with Alloxane-induced diabetes; D+C1: Rats treated with 125mg/kg/day; D+C2: Rats treated with 250mg/kg/day; D+C3: Rats treated with 375 mg/kg/day

Table 1: Effect of “Karkni” extract on lipid profile of alloxan-induced diabetic of rats.